Price movement over the last 24 hours
Amplitude Inc vs Tilray Brands Inc — how do they compare? Amplitude Inc trades at $9.21 (market cap $1.22B), while Tilray Brands Inc trades at $4.5 (market cap $544.44M). The key difference: Amplitude Inc is far larger — about 2.2× Tilray Brands Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| AMPL | TLRY | |
|---|---|---|
Market Cap | $1.22B | $544.44M |
Sector | Technology | Health |
52-Week High | $13.04 | $21.00 |
52-Week Low | $5.61 | $4.31 |
Enterprise Value | $1.05B | $641.59M |
Signals from Pluang's Aura AI — not financial advice
AMPL trades at $9.18, down 2.13% over the past day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, reaching $343.21M in 2025, yet the company remains unprofitable with a net income margin of -25.11%. Analyst consensus is bullish with a $9.25 price target, though recent news includes multiple law firm fraud investigations and a Bank of America downgrade citing profitability concerns.
The outlook hinges on AMPL's ability to translate robust revenue growth into profitability amid competitive pressures. Investment opportunity lies in potential margin expansion and market share gains, but risks include ongoing legal scrutiny, execution challenges, and persistent negative cash flows. The stock's near-term direction will likely be driven by upcoming earnings results and clarity on the fraud allegations.
TLRY trades at $4.42, up 0.68% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows low valuation ratios (P/S 0.55, P/B 0.35) but deep losses (net margin -156.67%) and negative cash flow from operations. Recent news highlights expansion in medical cannabis and new product launches, yet earnings misses and high debt-to-asset ratios signal ongoing challenges.
Outlook remains uncertain with profitability elusive; growth via acquisitions adds scale but not earnings. Analyst consensus is cautious (25% buy, 65% hold), reflecting skepticism about near-term turnaround. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles in the cannabis sector.
Trailing returns across standard periods
Latest headlines on both assets
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →